cancer therapy | GenomeWeb

cancer therapy

Central Park, NYC

From targeted metagenomics on almost 300 soil samples, researchers saw evidence for microbiome gene clusters associated with natural product biosynthesis in NYC parks.

The partners will combine genome editing approaches with Watson's computational and machine learning methods to study drug-resistance in tumors.

The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.

The researchers identified 122 potential immune response drivers that could serve as targets for drug research efforts.

The researchers identified new combinations of mutated genes and drugs that could provide the platform for future cancer therapies. 

Backed by $12 million from a recent Series A financing and a strategic partnership with Thermo Fisher Scientific, the Ann Arbor, Michigan-based firm plans to sequence the tumors of 100,000 advanced cancer patients over three years.

Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.

Elaine Mardis of Washington University in St. Louis described genome-guided efforts to identify neoantigen targets for cancer vaccines in melanoma and other cancer types.

In a JNCCN paper, the investigators discussed their efforts to comprehensively characterize a single patient's breast tumor and test potential treatments.

The work identified specific groups of somatic mutations that might be ideal to hunt for in ctDNA to monitor tumor burden, guide treatment, or follow therapeutic response.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.